WallStreetZen

NYSE: ABBV
AbbVie Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for ABBV

Based on 16 analysts offering 12 month price targets for AbbVie Inc.
Min Forecast
$96.00-13.14%
Avg Forecast
$114.38+3.49%
Max Forecast
$135.00+22.15%

Should I buy or sell ABBV stock?

Strong Buy
Strong Buy
12 analysts 66.67%
Buy
1 analysts 5.56%
Hold
5 analysts 27.78%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Forecast return on equity

Is ABBV forecast to generate an efficient return?
Company
140.19%
Industry
74.22%
Market
62.25%
ABBV's Return on Equity is forecast to be high in 4 years (140.19%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is ABBV forecast to generate an efficient return on assets?
Company
14.31%
Industry
16.87%
Market
19.66%
ABBV is forecast to generate lower Return on Assets (14.31%) than the US Drug Manufacturers - General industry average (16.87%)
Forecast

ABBV earnings per share forecast

What is ABBV's earnings per share in the next 3 years based on estimates from 8 analysts?
Avg 1 year Forecast
$12.17+156.13%
Avg 2 year Forecast
$13.61+186.56%
Avg 3 year Forecast
$12.21+157.12%
ABBV's earnings are forecast to grow at an exceptional rate of 40.08% per year
Forecast

ABBV revenue forecast

What is ABBV's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$54.0B+32.96%
Avg 2 year Forecast
$57.9B+42.36%
Avg 3 year Forecast
$54.2B+33.41%
ABBV's revenue is forecast to grow at a rate of 11.33% per year, which is not exceptional
Forecast

ABBV earnings growth forecast

How is ABBV forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
40.08%
Industry
24.82%
Market
20.47%
ABBV's earnings are forecast to grow faster (40.08% per year) than the US Drug Manufacturers - General industry average (24.82%)
Forecast
ABBV's earnings are forecast to grow faster (40.08% per year) than the US market average (20.47%)
Forecast
ABBV's earnings are forecast to grow faster (40.08% per year) than the risk-free savings rate (1.1%)
Forecast

ABBV revenue growth forecast

How is ABBV forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
11.33%
Industry
6.43%
Market
14.48%
ABBV's revenues are forecast to grow faster (11.33% per year) than the US Drug Manufacturers - General industry average (6.43%)
Forecast
ABBV's revenues are forecast to grow slower (11.33% per year) than the US market average (14.48%)
Forecast

AbbVie Stock Forecast FAQ

Is AbbVie Stock a good buy in 2020, according to Wall Street analysts?

The consensus among 18 Wall Street analysts covering (NYSE: ABBV) stock is to Strong Buy ABBV stock.

Out of 18 analysts, 12 (66.67%) are recommending ABBV as a Strong Buy, 1 (5.56%) are recommending ABBV as a Buy, 5 (27.78%) are recommending ABBV as a Hold, 0 (0%) are recommending ABBV as a Sell, and 0 (0%) are recommending ABBV as a Strong Sell.

What is ABBV's Price Target?

According to 16 Wall Street analysts that have issued a 1 year ABBV price target, the average ABBV price target is $114.38, with the highest ABBV stock price forecast at $135.00 and the lowest ABBV stock price forecast at $96.00.

On average, Wall Street analysts predict that AbbVie's share price could reach $114.38 by Jan 15, 2022. The average AbbVie stock price prediction forecasts a potential upside of 3.49% from the current ABBV share price of $110.52.

What is ABBV's earnings growth forecast for 2021-2023?

(NYSE: ABBV) AbbVie's forecast annual earnings growth rate of 40.08% is forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 24.82%, and and it is also forecast to beat the US market's average forecast earnings growth rate of 20.47%.

AbbVie's earnings in 2020 is $7,381,000,000.On average, 8 Wall Street analysts forecast ABBV's earnings for 2021 to be $21,471,490,721, with the lowest ABBV earnings forecast at $20,930,922,298, and the highest ABBV earnings forecast at $21,954,525,580. On average, 6 Wall Street analysts forecast ABBV's earnings for 2022 to be $24,022,380,695, with the lowest ABBV earnings forecast at $23,013,425,528, and the highest ABBV earnings forecast at $24,742,962,109.

In 2023, ABBV is forecast to generate $21,554,437,883 in earnings, with the lowest earnings forecast at $21,001,515,627 and the highest earnings forecast at $22,607,513,881.

What is ABBV's revenue growth forecast for 2021-2023?

(NYSE: ABBV) AbbVie's forecast annual revenue growth rate of 11.33% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.43%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.48%.

AbbVie's revenue in 2020 is $40,650,000,000.On average, 5 Wall Street analysts forecast ABBV's revenue for 2021 to be $95,388,908,687,316, with the lowest ABBV revenue forecast at $93,647,346,532,498, and the highest ABBV revenue forecast at $98,703,593,782,288. On average, 5 Wall Street analysts forecast ABBV's revenue for 2022 to be $102,127,183,207,204, with the lowest ABBV revenue forecast at $98,553,582,956,378, and the highest ABBV revenue forecast at $106,237,666,909,462.

In 2023, ABBV is forecast to generate $95,711,024,286,543 in revenue, with the lowest revenue forecast at $92,604,330,084,112 and the highest revenue forecast at $99,619,542,236,962.

What is ABBV's Earnings Per Share (EPS) forecast for 2021-2023?

(NYSE: ABBV) AbbVie's current Earnings Per Share (EPS) is $4.75. On average, analysts forecast that ABBV's EPS will be $12.17 for 2021, with the lowest EPS forecast at $11.86, and the highest EPS forecast at $12.44. On average, analysts forecast that ABBV's EPS will be $13.61 for 2022, with the lowest EPS forecast at $13.04, and the highest EPS forecast at $14.02. In 2023, ABBV's EPS is forecast to hit $12.21 (min: $11.90, max: $12.81).

What is ABBV's forecast return on equity (ROE) for 2021-2024?

(NYSE: ABBV) forecast ROE is 140.19%, which is considered strong.

What is ABBV's forecast return on assets (ROA) for 2021-2024?

(NYSE: ABBV) forecast ROA is 14.31%, which is lower than the forecast US Drug Manufacturers - General industry average of 16.87%.
WallStreetZen
©2021 WallStreetZen
Company
AboutBlogPrivacy PolicyTerms of ServiceContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatistics
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics